Cancer vaccine - OmicsDI

Show results for

Unknown (10636)
Genomics (359)
Transcriptomics (240)
Clinical (129)
Proteomics (109)
Models (14)
Genomic (12)
Other (9)
Metabolomics (6)
Methylation profiling (2)

Organisms

Mus musculus (163)
Homo sapiens (158)
Gallus gallus (27)
Ovis aries (20)
Dermestes lardarius (19)
Senegalia senegal (19)
Frangula alnus (19)
Pandalus borealis (19)
Pachymenia carnosa (19)
Bothrops moojeni (19)
Quercus alba (19)
Megathura crenulata (19)
Gossypium hirsutum (19)
Bos taurus (19)
Rhodotorula (18)
Medicago sativa (11)
Chlorocebus sabaeus (2)
Macaca fascicularis (2)
Schistosoma mansoni (2)
Ceratonia siliqua (2)
Oncorhynchus nerka (2)
Thymus (1)
Leptospira interrogans serovar Copenhageni str. Fiocruz L1-130 (1)
Helicobacter pylori P12 (1)
Salmonella enterica subsp. enterica serovar Paratyphi A (1)
Dirofilaria immitis (1)
Xenopus laevis (1)
Mycobacterium tuberculosis (1)
Mesocricetus auratus (1)
Plasmodium falciparum (1)

Organisms

Homo sapiens (135)
Mus musculus (124)
Macaca mulatta (5)
Gallus gallus (3)
Mycobacterium intracellulare subsp. intracellulare (1)
Necator americanus (1)
Pan troglodytes (1)
Escherichia phage T7 (1)
Chlorocebus aethiops (1)
Macaca (1)
Bos taurus (1)

Repository

ENA (335)
geo (175)
biostudies-arrayexpress (124)
pride (55)
dbGaP (12)
BioModels (11)
EGA (11)
MassIVE (11)
iProX (7)
MetaboLights (6)
Cell Collective (3)
jPOST (1)

Tissue

Cell culture (14)
Blood (10)
Bone marrow (6)
Mononuclear cell (5)
B cell (4)
Breast (4)
Dendritic cell (4)
Epithelial cell (4)
Liver (3)
Lung (3)
Peripheral blood mononuclear cell (3)
Brain (2)
Breast cancer cell (2)
Colon (2)
Epithelium of pancreatic duct (2)
Kidney (2)
Macrophage (2)
Pancreas (2)
Skin (2)
Astrocyte (1)
Blood cell (1)
Breast cancer cell line (1)
Central nervous system (1)
Embryonic stem cell (1)
Epithelial cell of lung (1)
Epithelial cell of skin gland (1)
Erythrocyte (1)
Esophagus (1)
HeLa cell (1)
T cell (1)

Disease

Colorectal Neoplasms (47)
Carcinoma (8)
Neoplasms (7)
Breast Neoplasms (4)
Colonic Neoplasms (4)
BCG Vaccine (3)
Advanced metastatic colorectal cancers (3)
Adenocarcinoma (3)
Colorectal cancer (3)
Lymphoma (2)
Melanoma (2)
Pancreatic Neoplasms (2)
Stomach Neoplasms (2)
Lung Neoplasms (2)
Colorectal cancer (2)
Prostate cancer (1)
2) lymphoid malignancies (1)
Adult both male and femal patients treated for colorectal cancer (1)
Prostate and colon cancer (1)
Colorectal Cancer, Stage 4 (1)
Malignant neoplasm of colon, Malignant neoplasm of rectosigmoid junction, Malignant neoplasm of rectum, Malignant neoplasm of anus and anal canal (1)
Thymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above) (1)
Carcinoma of colon and rectum (1)
Lung, breast, pancreas, stomach, and colorectal cancer (1)
Colorectal cancer metastatic (1)
Incurable lung, esophageal, colorectal, gastric, gallbladder, or breast cancer (1)
Survivin-expressing advanced/recurrent colorectal cancer patients or patients who refuse standard cancer therapy (1)
Colorectal cancer patients refractory to conventional treatments (1)
Advanced or recurrent gastric and colorectal cancer (1)
Advanced or recurrent colorectal cancer (1)

Technology Type

Mass Spectrometry (55)
Shotgun proteomics (27)
Affinity purification coupled with mass spectrometry proteomics (10)
Bottom-up proteomics (9)
Data-dependent acquisition (9)
Immunopeptidomics (7)
Mass spectrometry assay (4)
SWATH MS (3)
Mass spectrometry (2)
Data-independent acquisition (2)
Top-down proteomics (2)
Gel-based experiment (1)

Instrument Platform

Illumina NovaSeq 6000 (7)
NextSeq 500 (6)
Orbitrap Fusion Lumos (6)
Liquid Chromatography MS - negative - reverse phase (3)
Illumina HiSeq 2000 (2)
Liquid Chromatography MS - positive - reverse phase (2)
NEBNext Ultra II RNA Library Prep Kit (1)
NEBNext Globin and rRNA Depletion Kit (1)
PAXgene Blood RNA tubes (1)
NextSeq 1000 (1)
Illumina HiSeq X (1)
Illumina HiSeq 2500 (1)
LTQ Orbitrap Elite (1)
Orbitrap Fusion (1)
Q Exactive (1)
Q Exactive HF (1)
Q Exactive Plus (1)
QExactive Plus (1)
TimsTOF Pro 2 (1)
TripleTOF 5600 (1)
TripleTOF 6600 (1)
Liquid Chromatography MS - alternating - HILIC (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)

Publication Date

2025 (54)
2024 (41)
2026 (36)
2013 (32)
2015 (29)
2022 (27)
2021 (26)
2014 (19)
2023 (17)
2016 (16)
2020 (15)
2010 (14)
2019 (10)
2017 (10)
2009 (10)
2012 (8)
2011 (8)
2018 (5)
2008 (5)
2005 (3)
2006 (1)

UNIPROT ID/AC

Q3UNK5 (1)
P70293 (1)
C4NUM1 (1)
P01137 (1)

CHEBI ID

CHEBI:167922 (1)
CHEBI:32664 (1)
CHEBI:17536 (1)
CHEBI:15676 (1)
CHEBI:16708 (1)
CHEBI:16335 (1)
CHEBI:16449 (1)
CHEBI:16761 (1)

Metabolite Name

Aminovaleric acid betaine (1)
VaL-Gly (1)
Tiglyl carnitine C5:1 (1)
Taurodeoxycholic acid isomer (1)
Stearoylcarnitine isomer (1)
Sn-glycero-3-phospho-1-Inositol (1)
Ser Thr Glu isomer (1)
Sedoheptoluse-7-phosphate (1)
Saringosterol isomer (1)
Ribothymidine isomer (1)
Ribose-5-phosphate (1)
PS(22:1/20:4) (1)
PS(20:5/20:0) (1)
PS(20:1/18:2) (1)
Propionyl carnitine C3 (1)
PI(20:4/18:0) (1)
PG(22:6/17:1) (1)
PG(22:6/16:1) (1)
PG(22:2/16:1) (1)
PG(20:4/18:2) (1)
PG(20:4/18:1) (1)
PG(20:4/18:0) (1)
PG(20:4/16:1) (1)
PG(18:2/22:6) (1)
PG(18:1/22:6) (1)
PG(18:1/22:5) (1)
PG(16:1/20:5) (1)
PG(16:1/16:0) (1)
PG (22:6/18:3) (1)
PE(P-18:1/20:4) (1)

First Public Date

2025 (56)
2026 (45)
2024 (40)
2014 (36)
2023 (30)
2022 (24)
2017 (20)
2021 (18)
2019 (17)
2020 (16)
2015 (13)
2018 (8)
2016 (6)
2013 (6)

Modelling Approach

Ordinary differential equation model (9)

Study status

Completed (62)
Recruiting (18)
Terminated (16)
Active, not recruiting (10)
Withdrawn (8)
Not yet recruiting (8)
Not provided (5)
Ongoing (2)

Lab affiliation

Institute for Research in Immunology and Cancer, Department of Biochemistry, Department of Chemistry, Université de Montréal, Québec, Canada H3T 1J4 (5)
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany (2)
Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany (2)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Room 214, level 2, 15 Innovation Walk Monash Biomedicine Discovery Institute Monash University, Clayton Campus Clayton 3800 Victoria Australia (2)
Head of Laboratory of Neuro-Oncology, Neurology, Clinical & Cancer Proteomics (2)
International Centre for Cancer Vaccine Science, University of Gdansk (2)
International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, Gdansk, Poland (2)
VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium. Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. VIB Proteomics Core, VIB, Ghent, Belgium. (2)
1. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Germany 3. Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Germany 4. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Germany (1)
Additional Professor, Deptt. of Medical Oncology (Lab), Dr BRAIRCH, AIIMS, New Delhi (1)
BriaCell Therapeutics Corporation, Berkeley, CA, USA (1)
Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Pathum Wan, Bangkok, Thailand 10330 (1)
DKFZ F130 Division of Immunotherapy and Immunoprevention (1)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia (1)
Department of Biological Engineering, Massachusetts Institute of Technology (1)
Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA; The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA (1)
Department of Immunology, Interfaculty Institute for Cell Biology, Tübingen, Germany (1)
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR USA (1)
Department of Peptide-based Immunotherapy (1)
Dept. Oncology-Pathology, Scilifelab, Karolinska Institutet, Sweden (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology, Head Immunoproteomics Laboratory, Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Victoria, Australia (1)
Francis Impens, VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.Department of Biomolecular Medicine, Ghent, Belgium. VIB Proteomics Core, Ghent, Belgium (1)
Fudan Uninversity, Shanghai Cancer Center (1)
Genecology Research Centre, University of the Sunshine Coast (1)
IPBS-Toulouse BP64182 205 route de Narbonne 31077 Toulouse Cedex04 France (1)
Institute for Research in Immunology and Cancer, Department of Chemistry, Université de Montréal, Montréal, Québec, Canada H3T 1J4 (1)
International Center for Cancer Vaccine Science (ICCVS), University of Gdansk, Gdansk, Poland (1)
International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, 80-822 Gdansk, Poland (1)
Leibniz Institute for Experimental Virology (HPI), Germany; Centre for Structural Systems Biology, Germany; 5European XFEL GmbH, Germany. (1)
Massachusetts Institute of Technology (1)

Keyword

Vaccines (15)
Stage IV colon cancer (13)
Recurrent colon cancer (12)
Immunotherapy (11)
Sargramostim (10)
Stage IV rectal cancer (10)
Vaccine (9)
Recurrent rectal cancer (9)
Stage IV pancreatic cancer (8)
Stage III colon cancer (8)
Leucovorin (8)
Fluorouracil (8)
Recurrent pancreatic cancer (7)
Adenocarcinoma of the colon (7)
Nivolumab (6)
Adenocarcinoma of the rectum (6)
Cyclophosphamide (5)
Stage II pancreatic cancer (5)
Stage III pancreatic cancer (5)
Stage IV non-small cell lung cancer (5)
Stage IV breast cancer (5)
Recurrent breast cancer (5)
Recurrent non-small cell lung cancer (5)
Ipilimumab (5)
Bevacizumab (5)
Oxaliplatin (5)
Neoantigen cancer vaccine (4)
Poly ICLC (4)
Cancer vaccine (4)
Atezolizumab (4)

IsPrivate

False (11)

Submitter Keywords

Immuno-oncology (6)
Oncology (1)

Classification

helminths (1)
viruses (1)
bacteria (1)

Study type

Interventional (126)
Transcription profiling by array (76)
Proteomic profiling by array (18)
RNA-seq of coding RNA (11)
RNA-seq of coding RNA from single cells (7)
Observational (3)
Unknown experiment type (2)
Human - One-color microarray (2)
One-color microarray (1)
Animal - High-throughput sequencing (1)
Transcription profiling by RT-PCR (1)
ATAC-seq (1)
Ribo-seq (1)
DNA-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)

Release Date

2022 (1414)
2021 (1212)
2023 (1145)
2025 (980)
2024 (925)
2020 (797)
2019 (622)
2018 (561)
2016 (511)
2015 (463)
2017 (448)
2014 (405)
2013 (262)
2011 (208)
2012 (194)
2010 (155)
2026 (131)
2009 (88)
2008 (78)
2007 (36)
2006 (30)
2005 (30)
2003 (16)
2004 (15)
2001 (10)
2002 (6)
2000 (6)
1999 (6)
1998 (6)

Location

United States (66)
Japan (20)
China (6)
Netherlands (5)
Denmark (4)
Spain (4)
Australia (4)
United Kingdom (4)
Germany (3)
Israel (3)
Italy (3)
Iran (2)
Cuba (2)
Thailand (2)
Czechia (2)
Belgium (2)
Canada (2)
Switzerland (2)
France (2)
Singapore (1)
Puerto Rico (1)
Bulgaria (1)
Sweden (1)
South Korea (1)
Poland (1)
Argentina (1)
Brazil (1)
Hungary (1)
Austria (1)

Previous page
1 / 1152
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 1152
Next page

Sort by:

Relevance

Page size

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]

Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42163 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42175 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42176 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42179 | biostudies-arrayexpress

Wilson2012 - tumor vaccine efficacy

The paper describes a model of antitumor vaccine therapy. Created by COPASI 4.25 (Build 207) This model is described in the article: A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy Shelby Wilson and Doron Levy Bull Math Biol. 2012 July ; 74(7) Abstract: TGF-β ...

2024-09-02 | BIOMD0000000791 | BioModels

Immuno-oncology

GEP of PMBCs during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer (RCC) patients

Tumor-induced immunosuppression remains a major challenge for immunotherapy of cancer patients. To further elucidate why an allogeneic gene-modified (Interleukin-7(IL-7)/CD80 co-transfected) renal cell cancer vaccine failed to induce clinically relevant TH1-polarized immune responses, peripheral blo...

ORGANISM(S): Homo sapiens

2014-09-24 | E-GEOD-51490 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42019 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42020 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42145 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:200]